These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18835981)
1. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain. Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981 [TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976 [TBL] [Abstract][Full Text] [Related]
3. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Huron DR; Gorre ME; Kraker AJ; Sawyers CL; Rosen N; Moasser MM Clin Cancer Res; 2003 Apr; 9(4):1267-73. PubMed ID: 12684394 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571. Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011 [TBL] [Abstract][Full Text] [Related]
5. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
6. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617 [TBL] [Abstract][Full Text] [Related]
7. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018 [TBL] [Abstract][Full Text] [Related]
8. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Ren SY; Xue F; Feng J; Skorski T Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545 [TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Brasher BB; Roumiantsev S; Van Etten RA Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652 [TBL] [Abstract][Full Text] [Related]
10. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816 [TBL] [Abstract][Full Text] [Related]
11. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913 [TBL] [Abstract][Full Text] [Related]
12. Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480 [TBL] [Abstract][Full Text] [Related]
13. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide. Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832 [TBL] [Abstract][Full Text] [Related]
14. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Sato N; Narita M; Takahashi M; Yagisawa K; Liu A; Abe T; Nikkuni K; Furukawa T; Toba K; Aizawa Y Hematol Oncol; 2003 Jun; 21(2):67-75. PubMed ID: 12802811 [TBL] [Abstract][Full Text] [Related]
15. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Wozniak K; Czechowska A; Blasiak J Chem Biol Interact; 2004 Apr; 147(3):309-18. PubMed ID: 15135086 [TBL] [Abstract][Full Text] [Related]
16. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity. Juang JL; Hoffmann FM Oncogene; 1999 Sep; 18(37):5138-47. PubMed ID: 10498863 [TBL] [Abstract][Full Text] [Related]
17. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Van Etten RA; Debnath J; Zhou H; Casasnovas JM Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119 [TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase. Oda T; Kujovich J; Reis M; Newman B; Druker BJ Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092 [TBL] [Abstract][Full Text] [Related]